Earnings Call Summary | Nutex Health(NUTX.US) Q2 2024 Earnings Conference
Earnings Call Summary | Nutex Health(NUTX.US) Q2 2024 Earnings Conference
The following is a summary of the Nutex Health (NUTX) Q2 2024 Earnings Call Transcript:
以下是Nutex Health（NUTX）Q2 2024业绩会议呼叫记录摘要：
Financial Performance:
金融业绩：
Q2 2024 total revenue grew 29%, from $58.9 million to $76.1 million year-over-year.
Mature hospital revenue increased by 13.2% compared to Q2 2023.
Hospital division visits increased by 28% compared to the same quarter last year.
Gross profit for Q2 2024 was $22.6 million, a 134% increase over Q2 2023, representing a margin of 29.7%.
Adjusted EBITDA for Q2 2024 was $12 million, an increase of 200% compared to $4 million in Q2 2023.
Net loss improved significantly from $3.5 million in Q2 2023 to only $364,000 in Q2 2024.
Q2 2024总营业收入同比增长29％，从5,890万美元增至7,610万美元。
与Q2 2023相比，成熟医院的收入增长了13.2％。
医院部门的就诊人数同比增长28％。
Q2 2024的毛利润为2260万美元，较Q2 2023增长134％，占比29.7％。
Q2 2024调整后的EBITDA为1200万美元，较Q2 2023增长200％，为400万美元。
净亏损从Q2 2023的350万美元显着好转，仅为Q2 2024的364,000美元。
Business Progress:
业务进展：
Nutex Health is expanding with four new hospitals under construction, expected to open in the next 6-12 months in various locations including Idaho, Florida, Wisconsin, and Texas.
Planning to open one to three new hospitals per year beyond 2025.
Sold off less profitable assets to reinvest in more strategic areas.
Implemented a new HR software, Workday, to streamline operations and planning to introduce new labor management software.
Nutex Health正在扩张，并正在建设四家新医院，预计在接下来的6-12个月内在不同的地点，包括爱达荷州、佛罗里达州、威斯康星州和德克萨斯州开业。
计划在2025年后每年开设一至三家新医院。
出售利润较低的资产以重新投资更具战略性的领域。
实施了新的人力资源软件Workday，以简化运营，并计划引入新的劳动力管理软件。
Opportunities:
机会：
Positioned to meet the growing demand for healthcare, especially with an aging population ('silver tsunami').
Expanding the service mix at hospitals to increase inpatient and observation volumes, aiming for more comprehensive care within their facilities.
准备满足不断增长的医疗需求，特别是随着人口老龄化而来的“白银海啸”。
扩大医院的服务组合，增加住院和观察量，并旨在在其设施内提供更全面的护理。
Risks:
风险：
Arbitration process under the No Surprises Act could affect revenue if unsuccessful, despite previous favorable outcomes.
如果不成功，未来费用不得超过限额法仲裁程序可能会影响收入，尽管以前有过有利的结果。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。